Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totaling 4,577 shares, an increase of 1,702.0% from the April 15th total of 254 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 3 shares, the days-to-cover ratio is presently 1,525.7 days.
Basilea Pharmaceutica Stock Performance
OTCMKTS BPMUF remained flat at $69.00 during trading on Monday. The business has a fifty day simple moving average of $70.39 and a 200-day simple moving average of $66.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68. Basilea Pharmaceutica has a 52-week low of $57.70 and a 52-week high of $74.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital?treated diseases. The company’s research is focused primarily on anti?infectives and oncology, with a portfolio that spans both marketed products and early? to late?stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad?spectrum antifungal agent marketed under the trade name Cresemba.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
